Metabolic syndrome in Iran: a review

Article (Supplemental Material)


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/74806/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Obligatory criteria</strong></td>
<td>IR Diabetes mellitus/ IFG/ IGT evaluated by euglycemic clamp</td>
<td>IR or plasma insulin&gt;75th centile</td>
<td>Nil</td>
<td>IGT or IFG</td>
<td>Central obesity WC ≥94 cm (M) WC ≥80 cm (F)</td>
<td>Central obesity with ethnicity specific values</td>
<td>Using age-modified cut-points of ATPIII as published by Cook (2003) For a paediatric NHANES population[10]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Criteria</strong></td>
<td>IR plus 2 of 5 criteria below</td>
<td>Hyperinsulinemia plus 2 of 4 criteria below</td>
<td>At least 1 of the following CVD/ PCOS/ NAFLD/ Acanthosis nigricans Or FHx of T2DM/ HT or IGT Or Gestational DM or IGT</td>
<td>3 of 5 criteria below</td>
<td>Obesity plus 2 of 4 criteria below</td>
<td>3 of 5 criteria below</td>
<td>Score based on Z-scores standardised for age, gender and race. Cut-off based on area under ROC curve, and determined for specific population</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adiposity</strong></td>
<td>WHR&gt;0.9 (M) WHR&gt;0.85 (F) or BMI&gt;30 Kg/m²</td>
<td>WC ≥94 cm (M) WC ≥80 cm (F)</td>
<td>WC≥102 cm (M) WC≥88 cm (F)</td>
<td>BMI ≥25 and/or WC ≥102 cm (M) WC ≥88 cm (F) Plus 2 of the following</td>
<td>WC &gt;102 cm (M) &gt;88 cm (F)</td>
<td>-</td>
<td>Europid WC ≥94 cm (M) WC &gt;80 cm (F) Non Europid WC &gt;90 cm (M) WC &gt;80 cm (F) or BMI&gt;30 Kg/m²</td>
<td>Increased WC using population and country specific definitions</td>
<td>Standardised WC</td>
</tr>
<tr>
<td><strong>Blood pressure</strong></td>
<td>≥140/90 mmHg</td>
<td>≥140/90 mmHg or treatment</td>
<td>≥130/85 mmHg</td>
<td>≥130/85 mmHg</td>
<td>SBP≥130 mmHg, or DBP≥85 mmHg</td>
<td>SBP≥130 mmHg, or DBP≥85 mmHg, or treatment</td>
<td>SBP≥130 mmHg, or DBP≥85 mmHg, or treatment</td>
<td>SBP≥130 mmHg, or DBP≥85 mmHg, or treatment</td>
<td>Standardised mean arterial pressure (mmHg)</td>
</tr>
<tr>
<td><strong>IGT</strong></td>
<td>-</td>
<td>FG≥110 mg/dL (6.1 mmol/L)</td>
<td>FG≥110 mg/dL (6.1 mmol/L)</td>
<td>FG 110-125 mg/dL</td>
<td>FG&gt;100mg/dL or treatment</td>
<td>FG≥100mg/dL or T2DM</td>
<td>FG≥100mg/dL (5.6 mmol/L)</td>
<td>FG&gt;100mg/dL (5.6 mmol/L)</td>
<td>Standardised HOMA</td>
</tr>
<tr>
<td><strong>Dyslipidaemia</strong></td>
<td>Plasma TG≥150mg/dL or HDL-C &lt;35 mg/dL (M)</td>
<td>TG≥177mg/dL (2 mmol/L), or HDL-C &lt;39 mg/dL (L)</td>
<td>TG≥150 mg/dL HDL&lt;40 mg/dL (M)</td>
<td>TG≥150 mg/dL HDL&lt;40 mg/dL (M)</td>
<td>TG≥150mg/dL or treatment HDL-C &lt;40 mg/dL (M)</td>
<td>TG≥150mg/dL or treatment HDL-C &lt;40 mg/dL (M)</td>
<td>TG≥150mg/dL or treatment HDL-C &lt;40 mg/dL (M)</td>
<td>TG≥150mg/dL or treatment HDL-C &lt;40 mg/dL (M)</td>
<td>Standardised fasted TG and HDL</td>
</tr>
<tr>
<td>Other criteria</td>
<td>Micro-albuminuria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AACE = American association of Clinical Endocrinology  
CMetSyS = Continuous Metabolic syndrome Score  
CVD = Cardiovascular disease  
EGIR = European Group for the Study of Insulin Resistance  
F = female  
FG = Fasting glucose  
FHx = Family history;  
HDL-C = High density lipoprotein cholesterol  
HT = Hypertension;  
IFG = Impaired fasting glucose;  
IGT = Impaired glucose tolerance;  
IDF = International Diabetes Federation  
IR= insulin resistance;  
JIS -IDF/ AHA/ NHLBI = Joint Interim Societies-International Diabetes Federation/ American Heart Association/ National Heart Lung and Blood Institute;  
M = Male;  
Microalbuminuria = Urinary albumin excretion $\geq$20 ug/ min or Alb/ Creatinine ratio $\geq$30 mg/g;  
NAFLD = Non-alcoholic fatty liver disease;  
NCEP-ATPIII = National Cholesterol Education Programme-Adult Treatment Panel III  
PCOS = Polycystic ovary syndrome;  
T2DM = type 2 diabetes mellitus;  
TG = Triglycerides  
WC = Waist circumference  
WHO = World Health Organisation